In head and neck cancer, reports on the prognostic significance of B2M have been contradictory; high B2M levels have been associated with poor survival and increased metastatic potential in patients treated with primary surgery (17), while other reports suggest a negative prognostic impact of MHC-I loss, due to restricted immunosurveillance (18, 19). This evidence concerns the gene B2M and head and neck cancer.